Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Antiviral Res ; 75(1): 14-9, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17210189

RESUMO

A recombinant Eimeria protozoan protein antigen (rEA) has been shown to have antitumor and antiviral activity. The purpose of this study was to determine the effect of rEA treatment alone or in combination with an agonist cocktail consisting of granulocyte macrophage colony stimulating factor (GM-CSF), interferon gamma (IFN-gamma), interleukin 4 (IL-4), and anti CD-40 antibody, in the treatment of Banzi virus (BV) disease in BALB/c mice. Treatment with rEA resulted in a significant increase in survival, weight gain, and mean day to death in BV-infected mice and resulted in a significant decrease in brain virus titer. Treatment with rEA, in combination with a 4-agonist cocktail, improved disease parameters to a greater degree than rEA treatment alone. The effect of treatment with a reduced concentration of agonist cocktail or fewer components of the agonist cocktail, in combination with rEA, on disease outcome in BV-infected mice was also investigated. Treatment with rEA, alone or in combination with agonist cocktail, 24h after virus challenge did not improve disease. Treatment with rEA, alone or in combination with an agonist cocktail, is efficacious for the prophylaxis of BV infection in mice.


Assuntos
Eimeria/química , Infecções por Flavivirus/prevenção & controle , Flavivirus/efeitos dos fármacos , Proteínas de Protozoários/agonistas , Proteínas de Protozoários/uso terapêutico , Animais , Antígenos CD40/uso terapêutico , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Feminino , Flavivirus/genética , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Interferon gama/uso terapêutico , Interleucina-4/uso terapêutico , Camundongos , Camundongos Endogâmicos BALB C , Proteínas de Protozoários/genética , Proteínas de Protozoários/isolamento & purificação , Proteínas de Protozoários/farmacologia , Proteínas Recombinantes/agonistas , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêutico , Taxa de Sobrevida , Fatores de Tempo
2.
Virology ; 360(2): 454-60, 2007 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-17118420

RESUMO

Mice are used as models for western equine encephalitis virus (WEEV) infection, but high mortality is generally only seen with intracranial or intranasal challenge, while peripheral inoculation results in approximately 50% mortality and is not dose-dependent. Hamsters were therefore studied as a model for WEEV infection. Hamsters were highly sensitive to intraperitoneal (i.p.) infection with WEEV. Disease progression was rapid, and virus titers in serum, brain, liver, and kidney of infected hamsters peaked between 2 and 4 days post-virus inoculation (dpi). Foci of virus infection were detected in neurons of the cerebral cortex and midbrain. Pre-treatment i.p. with either interferon alfacon-1 (5 microg/kg/day) or with Ampligen (3.2 mg/kg/day) resulted in complete survival, reduced brain titers, and improved weight gain. This model of WEEV infection in hamsters appears to serve as a suitable model for the evaluation of potential therapeutic agents for the treatment of WEE disease.


Assuntos
Antivirais/uso terapêutico , Modelos Animais de Doenças , Vírus da Encefalite Equina do Oeste/efeitos dos fármacos , Encefalomielite Equina/tratamento farmacológico , Indutores de Interferon/uso terapêutico , Interferon Tipo I/uso terapêutico , Poli I-C/uso terapêutico , Poli U/uso terapêutico , Animais , Peso Corporal , Encéfalo/virologia , Córtex Cerebral/virologia , Cricetinae , Vírus da Encefalite Equina do Oeste/crescimento & desenvolvimento , Encefalomielite Equina/patologia , Encefalomielite Equina/virologia , Interferon-alfa , Rim/virologia , Fígado/virologia , Mesencéfalo/virologia , Mesocricetus , Proteínas Recombinantes , Soro/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA